Amorphous Naporafenib Dispersion for Oral Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (Compound A) is poorly soluble in aqueous media and has high permeability, posing challenges for formulating effective oral pharmaceutical compositions due to solubility and bioavailability issues.
Innovation Solution
Formulating Compound A as an amorphous solid dispersion with stabilizing polymers, such as hypromellose, to enhance solubility, bioavailability, and stability, allowing for high drug loading up to 80% and reducing tablet size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If Compound A is formulated as a crystalline form, then stability is improved, but solubility deteriorates
Solution Approach 1:
The patent transforms the crystalline form of Compound A into an amorphous form by changing the physical state parameters. This is achieved through specific processing conditions that prevent crystallization, resulting in a formulation with enhanced solubility while maintaining adequate stability through polymer stabilization.
Solution Approach 2:
The patent creates a composite system by combining Compound A with stabilizing polymers in an amorphous solid dispersion. The polymer matrix provides structural stability while the amorphous drug phase provides enhanced solubility, resolving the contradiction between these two properties.
2Productivity
If Compound A is formulated with high drug loading, then productivity is improved, but manufacturing precision deteriorates
Solution Approach 1:
The patent optimizes processing parameters including temperature, residence time, and cooling rates to enable high drug loading (up to 80% w/w) while maintaining formulation consistency. The amorphous solid dispersion process allows for precise control of drug-polymer ratios and uniform distribution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous solid dispersion formulations provide increased solubility, faster dissolution, and improved bioavailability of Compound A, achieving stable pharmaceutical compositions suitable for commercial scale-up.
Implementation Method 1
The present invention provides solid amorphous dispersions comprising N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (Compound A), or a pharmaceutically acceptable salt thereof, and one or more stabilizing polymers
Implementation Method 2
Compound A is poorly soluble in aqueous media and has a high permeability lending towards potential solubility and bioavailability issues that need to be addressed
Implementation Method 3
The amorphous solid dispersion formulations provide increased solubility, faster dissolution, and improved bioavailability of Compound A
Data Source
AI summary
The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition comprising N (3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2- (trifluoromethyl)isonicotinanmide, or a pharmaceutically acceptable salt thereof. The present invention also provides a process for preparing said pharmaceutical compositions for oral administration and methods of treatment with said pharmaceutical compositions.